|
| 37640175 | Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation. | Curr Probl Cardiol | 2024 |
| 36254670 | Individualized therapy in statin intolerance: the key to success. | Eur Heart J | 2023 |
| 37864578 | Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. | Eur Heart J | 2023 |
| 37558385 | Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. | JACC Heart Fail | 2023 |
| 37879804 | Ticagrelor-Induced Dyspnea: A Controllable Side Effect. | JACC Cardiovasc Interv | 2023 |
| 37641636 | Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. | Eur Heart J Open | 2023 |
| 35596030 | Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. | Sleep Breath | 2023 |
| 37345760 | Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. | J Am Heart Assoc | 2023 |
| 37311602 | Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. | BMJ Open Diabetes Res Care | 2023 |
| 37003273 | Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. | Lancet Healthy Longev | 2023 |
| 37069970 | Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial. | Kidney Int Rep | 2023 |
| 37223853 | In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show? | Curr Atheroscler Rep | 2023 |
| 36889425 | Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. | Am J Kidney Dis | 2023 |
| 36915035 | Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic. | J Am Heart Assoc | 2023 |
| 36843558 | Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. | Diabetes Obes Metab | 2023 |
| 36702781 | Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. | J Clin Endocrinol Metab | 2023 |
| 36594154 | Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. | Diabetes Obes Metab | 2023 |
| 36303404 | Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. | Eur Heart J | 2023 |
| 36350612 | Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10⿯000 Patients Across a Diverse Health Care Network. | JAMA Cardiol | 2023 |
| 35980763 | A polygenic risk score predicts atrial fibrillation in cardiovascular disease. | Eur Heart J | 2023 |
| 36394384 | Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin. | Diabetes Obes Metab | 2023 |
| 33258897 | Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. | Eur Heart J Cardiovasc Pharmacother | 2022 |
| 35603908 | Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. | Diabetes Obes Metab | 2022 |
| 35691283 | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. | Am J Nephrol | 2022 |
| 35486404 | Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. | JAMA Netw Open | 2022 |
| 35589614 | Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. | Diabetes Obes Metab | 2022 |
| 36440852 | 20 Years of Critical Pathways. | Crit Pathw Cardiol | 2022 |
| 36456073 | Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney Disease. | JACC Heart Fail | 2022 |
| 36250667 | Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS. | J Am Heart Assoc | 2022 |
| 35967112 | Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A <i>post hoc</i> Analysis from the Randomized VERTIS CV Trial. | Kidney Int Rep | 2022 |
| 35994565 | Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial. | Circulation | 2022 |
| 35929472 | Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. | J Am Heart Assoc | 2022 |
| 36302584 | Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. | J Am Coll Cardiol | 2022 |
| 36124341 | Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). | Clin Cardiol | 2022 |
| 36260325 | Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. | JAMA Cardiol | 2022 |
| 36117951 | Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate? | Eur Heart J Open | 2022 |
| 36153643 | A remote hypertension management program clinical algorithm. | Clin Cardiol | 2022 |
| 34910136 | Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. | Eur Heart J | 2022 |
| 35063969 | Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. | Clin J Am Soc Nephrol | 2022 |
| 34998708 | Impact of coronary artery calcium testing on patient management. | J Cardiovasc Comput Tomogr | 2022 |
| 35238955 | Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. | Diabetologia | 2022 |
| 35086664 | Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. | J Am Coll Cardiol | 2022 |
| 35325103 | Statin intolerance: how common is it and how do we work with patients to overcome it? | Eur Heart J | 2022 |
| 35266296 | Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. | Diabetes Obes Metab | 2022 |
| 35112882 | Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. | J Am Heart Assoc | 2022 |
| 35233908 | The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. | Diabetes Obes Metab | 2022 |
| 35166429 | Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. | Diabetes Obes Metab | 2022 |
| 35105533 | A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. | EuroIntervention | 2022 |
| 34481756 | Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. | Am Heart J | 2022 |
| 34774485 | LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. | J Lipid Res | 2022 |